Federated Hermes, Inc. Apellis Pharmaceuticals, Inc. Transaction History

Federated Hermes, Inc.

$43.6 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $27.9 Million - $33.9 Million	-363,837 Reduced 71.16%	147,465 $13.4 Million
Q1 2023 May 08, 2023	BUY	$46.59 - $66.96 $3.49 Million - $5.02 Million	75,002 Added 17.19%	511,302 $33.7 Million
Q4 2022 Feb 13, 2023	BUY	$43.24 - $61.04 $3.68 Million - $5.2 Million	85,197 Added 24.27%	436,300 $22.6 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $15.7 Million - $24.5 Million	351,103 New	351,103 $24 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $107,497 - $171,912	-3,497 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$31.4 - $69.84 $7.34 Million - $16.3 Million	-233,757 Reduced 98.53%	3,497 $115,000
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $7.55 Million - $12 Million	184,588 Added 350.49%	237,254 $15 Million
Q1 2021 May 13, 2021	SELL	$40.8 - $57.39 $2.63 Million - $3.71 Million	-64,564 Reduced 55.07%	52,666 $2.26 Million
Q4 2020 Feb 12, 2021	BUY	$30.79 - $57.2 $3.61 Million - $6.71 Million	117,230 New	117,230 $6.71 Million
Q1 2020 May 13, 2020	SELL	$17.91 - $44.33 $25,682 - $63,569	-1,434 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$22.1 - $30.8 $3.61 Million - $5.03 Million	-163,197 Reduced 99.13%	1,434 $44,000
Q3 2019 Nov 14, 2019	BUY	$24.09 - $32.18 $3.93 Million - $5.25 Million	163,217 Added 11542.93%	164,631 $3.97 Million
Q2 2019 Aug 14, 2019	SELL	$18.0 - $25.34 $3,510 - $4,941	-195 Reduced 12.12%	1,414 $36,000
Q1 2019 May 10, 2019	SELL	$12.81 - $19.82 $1,870 - $2,893	-146 Reduced 8.32%	1,609 $31,000
Q4 2018 Feb 13, 2019	SELL	$11.47 - $18.71 $6,446 - $10,515	-562 Reduced 24.26%	1,755 $23,000
Q3 2018 Nov 13, 2018	SELL	$16.57 - $21.03 $16,735 - $21,240	-1,010 Reduced 30.36%	2,317 $41,000
Q2 2018 Aug 10, 2018	BUY	$19.63 - $30.0 $5,555 - $8,490	283 Added 9.3%	3,327 $73,000
Q1 2018 May 09, 2018	BUY	$14.01 - $26.02 $42,646 - $79,204	3,044 New	3,044 $67,000

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

Wellington Management Group LLP Boston, MA

15.6M
Shares

$516 Million
0.08% of portfolio
Eco R1 Capital, LLC San Francisco, CA

11.9M
Shares

$394 Million
14.88% of portfolio
Avoro Capital Advisors LLC New York, NY

11.1M
Shares

$368 Million
4.82% of portfolio
Vanguard Group Inc Valley Forge, PA

9.82M
Shares

$325 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.8M
Shares

$192 Million
0.01% of portfolio

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account